2C-B-BUTTERFLY
2C-B-BUTTERFLY is a conformationally-restricted derivative of the phenethylamine hallucinogen 2C-B, which was discovered in 1999 by Michael S. Whiteside and Aaron Monte.[1] It is a ring-expanded homologue of the better known compound 2C-B-FLY, and has similar properties as an agonist for serotonin receptors, but with more selectivity for 5-HT2C over 5-HT2A.[2][3]
![]() | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C14H18BrNO2 |
| Molar mass | 312.202 g/mol g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Analogues and derivatives
Analogues and derivatives of 2C-B:
- 2C-B-FLY
- 2CBFly-NBOMe (NBOMe-2CB-Fly)
Other:
- 2C-B-AN
- 2C-B-BUTTERFLY
- 2C-B-DragonFLY
- 2CB-5-hemifly
- 2CB-Ind
- βk-2C-B (beta-keto 2C-B)
- TCB-2 (2C-BCB)
Legal Status
2C-B-BUTTERFLY is illegal in Latvia.[4]
See also
- Bromo-DragonFLY
- βk-2C-B
- 2C-D-5-EtO
References
- Whiteside, MS. Synthesis of hexahydrobenzodipyrans as ring-expanded analogues of potent serotonin 5-HT2A/2C receptor probes. UW-LaCrosseJUR, 1999; 2: 61–68.
- Whiteside MS, Kurrasch-Orbaugh D, Marona-Lewicka D, Nichols DE, Monte A. Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. Bioorg. Med. Chem 2002; 10(10): 3301–3306. doi: 10.1016/S0968-0896(02)00209-2
- Schultz DM, Prescher JA, Kidd, S; Marona-Lewicka, D; Nichols, DE; Monte, A. ‘Hybrid’ benzofuran–benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorg. Med. Chem 2008; 16(11): 6242–6251. doi: 10.1016/j.bmc.2008.04.030
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem
| Phenethylamines |
|
|---|---|
| Amphetamines |
|
| Phentermines |
|
| Cathinones |
|
| Phenylisobutylamines | |
| Phenylalkylpyrrolidines | |
| Catecholamines (and close relatives) |
|
| Miscellaneous |
|
| Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.
